4-{[2-(1-methyl-1H-imidazol-4-yl)ethyl]carbamoyl}butanoic acid | 1187618-19-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-{[2-(1-methyl-1H-imidazol-4-yl)ethyl]carbamoyl}butanoic acid
• 英文别名: 5-[2-(1-methylimidazol-4-yl)ethylamino]-5-oxopentanoic acid
• CAS: 1187618-19-4
• 化学式: C₁₁H₁₇N₃O₃
• 分子量: 239.27
• InChiKey: XAYAYPQLEGFLIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  84.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES
  申请人：OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"

  公开号：US20170183318A1

  公开（公告）日：2017-06-29

  The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

  本发明涉及医学，包括一种用于预防和治疗由RNA-和DNA-含病毒引起的疾病以及相关疾病的方法，其中该方法包括使用通式I的化合物或其药用可接受盐的有效量。该发明还涉及制备上述化合物的方法，用于预防或治疗由RNA-和DNA-含病毒引起的疾病的药物组合物，该组合物包括通式I的化合物或其药用可接受盐的有效量。该发明解决了提供一种新型药剂的目标，用于治疗属于肠病毒、副呼吸道病毒、呼吸道病毒、呼吸道病毒或阿尔法冠状病毒属的RNA-含病毒引起的疾病，和/或属于腺病毒科和/或疱疹病毒科的DNA-含病毒引起的疾病，并在预防和治疗哮喘急性发作、慢性阻塞性肺疾病、黏液囊病、结膜炎、胃肠炎、肝炎、心肌炎；在预防和治疗流涕、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道梗阻综合征方面具有有效性。
• GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES
  申请人：Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises"

  公开号：EP3722290A1

  公开（公告）日：2020-10-14

  The present invention relates to a novel biologically active glutarimide derivative of the following formula or a pharmaceutically acceptable salt thereof: Moreover, the present invention relates to the glutarimide derivative or the pharmaceutically acceptable salt thereof for use in the treatment of a respiratory tract disease, to a pharmaceutical composition for use in the treatment of a respiratory tract disease comprising an effective amount of the glutarimide derivative or the pharmaceutically acceptable salt thereof, and to a method for preparing the glutarimide derivative or the pharmaceutically acceptable salt thereof.

  本发明涉及下式的新型生物活性戊二酰亚胺衍生物或其药学上可接受的盐： 此外，本发明涉及用于治疗呼吸道疾病的戊二酰亚胺衍生物或其药学上可接受的盐，涉及用于治疗呼吸道疾病的药物组合物，其中包含有效量的戊二酰亚胺衍生物或其药学上可接受的盐，还涉及制备戊二酰亚胺衍生物或其药学上可接受的盐的方法。